{"article_title": "Chrono Therapeutics nets Rock Health investment for smoking cessation wearable", "article_keywords": ["quit", "therapeutics", "chrono", "technology", "million", "wearable", "device", "smartstop", "nicotine", "health", "smokers", "rock", "cessation", "smoking", "digital", "nets", "investment"], "article_url": "http://medcitynews.com/2015/03/rock-health-makes-first-investment-anti-smoking-wearable/", "article_text": "Rock Health entered the arena of digital health tools for smoking cessation with an investment in Chrono Therapeutics, according to a company statement. The pharmaceutical company produces a wearable drug delivery tool and companion app called SmartStop, which functions as a digital health coach to help smokers quit. The investment follows a $32 million Series A round in June.\n\nThe device is worn on the arm or body and delivers nicotine in doses through disposable cartridges. It is automatically times to release nicotine when each smoker experiences spikes in cravings. It transmits messages to a companion app through Bluetooth that let users know how much nicotine they\u2019ve had, provides alerts and encouraging messages. It is aimed at the majority of the 45 million smokers who want to quit. About 23 million try to quit smoking each year, according to data from the Centers for Disease Control.\n\nIn an interview with Wired magazine, CEO Dr Alan Levy compared its device to Fitbit but one that provides therapy. The device initially gives high doses of nicotine and gradually reduces that dose over a 10-week period. It also sees applications for technology for asthma, depression and ADHD.\n\nAdvertisement\n\nRock Health is investing $100,000 in Chrono, which is using the funding to support clinical trials of SmartStop, according to an emailed statement. Other investors include Canaan Partners, 5AM Ventures, Fountain Healthcare Partners, Mayo Clinic and GE Ventures. The company, which got its start in 2004, is hoping to get FDA approval for its device by 2017.\n\nRock Health Managing Director Malay Gandhi said its investment was spurred by an interest in supporting next generation product technology \u201cChrono\u2019s SmartStop drug delivery system represents the type of next-generation product technology that Rock Health is seeking to identify and advance in order to significantly impact the future of healthcare. By adopting digital technology to deliver and target treatment along with guided coaching, SmartStop is designed to help smokers quit their addictive, life-threatening habit with a reliable, convenient and effective wearable device.\u201d", "article_metadata": {"description": "Rock Health entered the arena of digital health tools for smoking cessation with an investment in Chrono Therapeutics, according to a company statement. The pharmaceutical company produces a wearable drug delivery tool and companion app called SmartStop, which functions as a digital health coach to help smokers quit. The investment follows a $32 million Series A round in June. The device is worn on the arm or body and delivers nicotine in doses through disposable cartridges. It is automatically times to release nicotine when each smoker experiences spikes in cravings. It transmits messages to a companion app through Bluetooth that let users know how much nicotine they\u2019ve had, provides alerts and encouraging messages. It is aimed at the majority of the 45 million smokers who want to quit. About 23 million try to quit smoking each year, according to data from the Centers for Disease Control. In an interview with Wired magazine, CEO Dr Alan Levy compared its device to Fitbit but one that provides therapy. The device initially gives high doses of nicotine and gradually reduces that dose over a 10-week period. It also sees applications for technology for asthma, depression and ADHD. Rock Health is investing $100,000 in Chrono, which is using the funding to support clinical trials of SmartStop, according to an emailed statement. Other investors include Canaan Partners, 5AM Ventures, Fountain Healthcare Partners, Mayo Clinic and GE Ventures. The company, which got its start in 2004, is hoping to get FDA approval for its device by 2017. Rock Health Managing Director Malay Gandhi said its investment was spurred by an interest in supporting next generation product technology \u201cChrono\u2019s SmartStop drug delivery system represents the type of next-generation product technology that Rock Health is seeking to identify and advance in order to significantly impact the future of healthcare. By adopting digital technology to deliver and target treatment along with guided coaching, SmartStop is designed to help smokers quit their addictive, life-threatening habit with a reliable, convenient and effective wearable device.\u201d", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "Rock Health entered the arena of digital health tools for smoking cessation with an investment in Chrono Therapeutics, according to a company statement. The pharmaceutical company produces a wearable drug delivery tool and companion app called SmartStop, which functions as a digital health coach to help smokers quit. The investment follows a $32 million Series A round in June. The device is worn on the arm or body and delivers nicotine in doses through disposable cartridges. It is automatically times to release nicotine when each smoker experiences spikes in cravings. It transmits messages to a companion app through Bluetooth that let users know how much nicotine they\u2019ve had, provides alerts and encouraging messages. It is aimed at the majority of the 45 million smokers who want to quit. About 23 million try to quit smoking each year, according to data from the Centers for Disease Control. In an interview with Wired magazine, CEO Dr Alan Levy compared its device to Fitbit but one that provides therapy. The device initially gives high doses of nicotine and gradually reduces that dose over a 10-week period. It also sees applications for technology for asthma, depression and ADHD. Rock Health is investing $100,000 in Chrono, which is using the funding to support clinical trials of SmartStop, according to an emailed statement. Other investors include Canaan Partners, 5AM Ventures, Fountain Healthcare Partners, Mayo Clinic and GE Ventures. The company, which got its start in 2004, is hoping to get FDA approval for its device by 2017. Rock Health Managing Director Malay Gandhi said its investment was spurred by an interest in supporting next generation product technology \u201cChrono\u2019s SmartStop drug delivery system represents the type of next-generation product technology that Rock Health is seeking to identify and advance in order to significantly impact the future of healthcare. By adopting digital technology to deliver and target treatment along with guided coaching, SmartStop is designed to help smokers quit their addictive, life-threatening habit with a reliable, convenient and effective wearable device.\u201d", "title": "Chrono Therapeutics nets Rock Health investment for smoking cessation wearable", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/chrono-watch.png", "updated_time": "2015-03-03T07:10:54-04:00", "url": "http://medcitynews.com/2015/03/rock-health-makes-first-investment-anti-smoking-wearable/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/chrono-watch.png", "description": "Rock Health entered the arena of digital health tools for smoking cessation with an investment in Chrono Therapeutics, according to a company statement. The pharmaceutical company produces a wearable drug delivery tool and companion app called SmartStop, which functions as a digital health coach to help smokers quit. The investment follows a $32 million Series A round in June. The device is worn on the arm or body and delivers nicotine in doses through disposable cartridges. It is automatically times to release nicotine when each smoker experiences spikes in cravings. It transmits messages to a companion app through Bluetooth that let users know how much nicotine they\u2019ve had, provides alerts and encouraging messages. It is aimed at the majority of the 45 million smokers who want to quit. About 23 million try to quit smoking each year, according to data from the Centers for Disease Control. In an interview with Wired magazine, CEO Dr Alan Levy compared its device to Fitbit but one that provides therapy. The device initially gives high doses of nicotine and gradually reduces that dose over a 10-week period. It also sees applications for technology for asthma, depression and ADHD. Rock Health is investing $100,000 in Chrono, which is using the funding to support clinical trials of SmartStop, according to an emailed statement. Other investors include Canaan Partners, 5AM Ventures, Fountain Healthcare Partners, Mayo Clinic and GE Ventures. The company, which got its start in 2004, is hoping to get FDA approval for its device by 2017. Rock Health Managing Director Malay Gandhi said its investment was spurred by an interest in supporting next generation product technology \u201cChrono\u2019s SmartStop drug delivery system represents the type of next-generation product technology that Rock Health is seeking to identify and advance in order to significantly impact the future of healthcare. By adopting digital technology to deliver and target treatment along with guided coaching, SmartStop is designed to help smokers quit their addictive, life-threatening habit with a reliable, convenient and effective wearable device.\u201d", "card": "summary", "title": "Chrono Therapeutics nets Rock Health investment for smoking cessation wearable - MedCity News"}, "fb": {"app_id": 148725768475669}, "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,California, Chrono Therapeutics, investing, pharmaceuticals, Rock Health, San Francisco, smoking, Wearables, , MedCity News", "article": {"section": "Daily", "tag": "Wearables", "published_time": "2015-03-03T06:50:16-04:00", "modified_time": "2015-03-03T07:10:54-04:00"}, "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "_id": "\"57477af46914bd0286fd989a\"", "article_summary": "Rock Health entered the arena of digital health tools for smoking cessation with an investment in Chrono Therapeutics, according to a company statement.\nThe pharmaceutical company produces a wearable drug delivery tool and companion app called SmartStop, which functions as a digital health coach to help smokers quit.\nIt is aimed at the majority of the 45 million smokers who want to quit.\nAbout 23 million try to quit smoking each year, according to data from the Centers for Disease Control.\nAdvertisementRock Health is investing $100,000 in Chrono, which is using the funding to support clinical trials of SmartStop, according to an emailed statement."}